Latest News
Latest News
Semaglutide May Increase Risk of Disease Causing Vision Loss
Retrospective study finds increased risk for NAION for patients with T2D and overweight or obesity taking semaglutide.
From the Journals
Weight Loss Drugs Cut Cancer Risk in Diabetes Patients
Researchers examine electronic health records of patients who had type 2 diabetes, no prior diagnosis of obesity-related cancers, and had been...
Latest News
Feds May End Hospital System’s Noncompete Contract for Part-Time Docs
NLRB issued a complaint against Mount Sinai Health System for contracts that request confidentiality, bar docs from poaching.
Latest News
Can Cannabis Help to Reduce Diabetes Risk?
People who used CBD had reduced inflammation and increased physical activity, research finds.
Latest News
Can Response to Semaglutide Be Predicted With a Genetic Test?
AI genetic testing may help identify patients who would benefit from semaglutide, by identifying abnormal postprandial satiety.
From the Journals
Urticaria Linked to Higher Cancer Risk, Study Finds
Researchers compare the incident cancer risk between patients with urticaria and the general population using data from Danish healthcare...
Latest News
GLP-1 Thyroid Warning Could Increase Overdiagnosis
A boxed warning about thyroid cancer risk with GLP-1s could lead to unnecessary screening, expert says.
Commentary
Facial Temperature Can Reveal Age and Disease
Research points to use of facial temperature to determine age, health, diet, and sleep, says physician.
Latest News
What Should Be Prioritized in Managing Early Diabetes?
ADA meeting debate on what to treat first in early diabetes included obesity, glucose, remission as priorities.
Latest News
Triple Therapy May Be Effective in Drug-Naive T2D
Combo of metformin, dapagliflozin, and saxagliptin could reduce body weight and adverse events, compared with step-wise therapy.
Feature
Time Warp: Fax Machines Still Common in Oncology Practice. Why?
Oncologists are among the many specialists across the country at the mercy of telecopiers.